• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

司美格鲁肽逆转高钾性周期性麻痹的慢性肌病:一例报告

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.

作者信息

Brand Kenneth, Landry Daniel, Mulhern Jeffrey, Braden Gregory

机构信息

UMASS Chan Baystate Medical Center, Springfield, USA.

出版信息

BMC Nephrol. 2025 Apr 7;26(1):179. doi: 10.1186/s12882-025-04068-5.

DOI:10.1186/s12882-025-04068-5
PMID:40197299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11977914/
Abstract

BACKGROUND

Hyperkalemic Periodic Paralysis (hyperPP) is an autosomal dominant genetic disorder where high extracellular potassium is associated with skeletal muscle depolarization and both flaccid muscle weakness as well as delayed muscle relaxation that can lead to myotonia and myopathy. Interventions have typically relied on avoidance of triggers, low potassium diets, and diuretics like acetazolamide and diclofenamide with limited success.

CASE PRESENTATION

The patient is a 48 year old man with hyperPP from a familial autosomal dominant sodium channel point mutation in the SCN4A gene at position 704 with a Threonine to Methionine substitution that lead to symptoms starting in early childhood. By age 30 he developed permanent muscle weakness and neither acetazolamide nor diclofenamide as interventions had improved his myopathy. In the spring of 2023, semaglutide was initiated for weight loss. Before the semaglutide he could not rise out of a chair without help and his gait was very slow. Over the next year his strength and quality of life returned to levels he had not had in decades.

CONCLUSION

This is a promising alternative treatment for hyperPP. By directly acting on skeletal muscle both dependent and independent of insulin, Semaglutide and likely other Glucagon-like peptide agonists show promise as a novel once weekly option that may treat not just the hyperkalemic periodic paralysis but also the skeletal muscle atrophy in a multimodal way.

摘要

背景

高钾性周期性麻痹(hyperPP)是一种常染色体显性遗传病,细胞外钾离子水平升高与骨骼肌去极化相关,会导致弛缓性肌无力以及肌肉舒张延迟,进而引发肌强直和肌病。治疗方法通常依赖于避免诱因、低钾饮食以及使用乙酰唑胺和双氯芬酰胺等利尿剂,但效果有限。

病例报告

该患者为一名48岁男性,患有高钾性周期性麻痹,其家族性常染色体显性遗传的SCN4A基因在704位发生点突变,苏氨酸被甲硫氨酸取代,导致症状始于幼儿期。到30岁时,他出现了永久性肌无力,乙酰唑胺和双氯芬酰胺作为治疗手段均未能改善其肌病。2023年春季,开始使用司美格鲁肽进行减肥。在使用司美格鲁肽之前,他在无人帮助的情况下无法从椅子上起身,步态非常缓慢。在接下来的一年里,他的力量和生活质量恢复到了几十年来未曾有过的水平。

结论

这是一种有前景的高钾性周期性麻痹替代治疗方法。司美格鲁肽以及其他可能的胰高血糖素样肽激动剂通过直接作用于骨骼肌,无论是否依赖胰岛素,都显示出有望成为一种新型的每周一次的治疗选择,不仅可以治疗高钾性周期性麻痹,还可以以多模式方式治疗骨骼肌萎缩。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef35/11977914/2e66b6b7fd17/12882_2025_4068_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef35/11977914/2e66b6b7fd17/12882_2025_4068_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef35/11977914/2e66b6b7fd17/12882_2025_4068_Fig1_HTML.jpg

相似文献

1
Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.司美格鲁肽逆转高钾性周期性麻痹的慢性肌病:一例报告
BMC Nephrol. 2025 Apr 7;26(1):179. doi: 10.1186/s12882-025-04068-5.
2
Long-term effectiveness of acetazolamide on permanent weakness in hyperkalemic periodic paralysis.乙酰唑胺治疗高钾型周期性瘫痪永久性无力的长期疗效。
Neuromuscul Disord. 2013 May;23(5):445-9. doi: 10.1016/j.nmd.2013.02.007. Epub 2013 Mar 7.
3
[A case of hyperkalemic periodic paralysis presenting progressive myopathy with tubular aggregates].[一例伴有管状聚集物的高钾性周期性麻痹呈现进行性肌病]
Rinsho Shinkeigaku. 2018 Nov 28;58(11):663-667. doi: 10.5692/clinicalneurol.cn-001137. Epub 2018 Oct 27.
4
Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals.高钾型周期性瘫痪的特征:对基因诊断个体的调查。
J Neurol. 2013 Oct;260(10):2606-13. doi: 10.1007/s00415-013-7025-9. Epub 2013 Jul 25.
5
Hyperkalemic periodic paralysis associated with a novel missense variant located in the inner pore of Nav1.4.与位于 Nav1.4 内孔的新型错义变异相关的高钾周期性瘫痪。
Brain Dev. 2023 Apr;45(4):205-211. doi: 10.1016/j.braindev.2022.12.003. Epub 2023 Jan 9.
6
Treatment for periodic paralysis.周期性麻痹的治疗。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD005045. doi: 10.1002/14651858.CD005045.pub2.
7
Severe infantile hyperkalaemic periodic paralysis and paramyotonia congenita: broadening the clinical spectrum associated with the T704M mutation in SCN4A.重度婴儿高钾性周期性麻痹和先天性副肌强直:扩大与SCN4A基因T704M突变相关的临床谱。
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1339-41. doi: 10.1136/jnnp.74.9.1339.
8
A dangerous food binge: a case report of hypokalemic periodic paralysis and review of current literature.危险的食物暴食:低钾周期性瘫痪病例报告及文献复习。
Ital J Pediatr. 2022 Jul 15;48(1):116. doi: 10.1186/s13052-022-01315-5.
9
Disappearance of episodic weakness during pregnancy in hyperkalemic periodic paralysis from the SCNA4 mutation T704M.携带SCNA4基因突变T704M的高钾性周期性麻痹患者孕期发作性肌无力消失。
Neurologist. 2009 Sep;15(5):289-90. doi: 10.1097/NRL.0b013e31818fc765.
10
Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report.司美格鲁肽,一种长效胰高血糖素样肽-1类似物,用于治疗因黑皮质素4受体缺陷导致的早发性肥胖:一例报告。
Horm Res Paediatr. 2025;98(2):148-155. doi: 10.1159/000537921. Epub 2024 Feb 23.

本文引用的文献

1
Effect of glucagon-like peptide-1 receptor agonist on insulin secretion index and serum Wnt5a protein in patients with new-onset type 2 diabetes mellitus.胰高血糖素样肽-1受体激动剂对新诊断2型糖尿病患者胰岛素分泌指数及血清Wnt5a蛋白的影响
J Diabetes Metab Disord. 2023 Jan 3;22(1):539-545. doi: 10.1007/s40200-022-01175-0. eCollection 2023 Jun.
2
An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism.一种有效的胰高血糖素样肽-1 受体激动剂,司美格鲁肽,通过调节骨骼肌代谢改善肥胖小鼠的肌少症性肥胖。
Drug Des Devel Ther. 2022 Oct 25;16:3723-3735. doi: 10.2147/DDDT.S381546. eCollection 2022.
3
Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis.
通过抑制肌纤维坏死性细胞凋亡改善炎症性肌病。
J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2118-2131. doi: 10.1002/jcsm.13025. Epub 2022 Jun 30.
4
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
5
Wingless-type MMTV integration site family member 5a: a novel biomarker regulated in type 2 diabetes mellitus and diabetic kidney disease.无翼型MMTV整合位点家族成员5a:一种在2型糖尿病和糖尿病肾病中受调控的新型生物标志物。
J Diabetes Metab Disord. 2019 Nov 22;18(2):525-532. doi: 10.1007/s40200-019-00461-8. eCollection 2019 Dec.
6
Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.胰高血糖素样肽-1 受体激动剂改善肌肉萎缩引起的肌肉减少症。
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):903-918. doi: 10.1002/jcsm.12434. Epub 2019 Apr 24.
7
GLP-1: Molecular mechanisms and outcomes of a complex signaling system.GLP-1:一个复杂信号系统的分子机制和结果。
Neurochem Int. 2019 Sep;128:94-105. doi: 10.1016/j.neuint.2019.04.010. Epub 2019 Apr 17.
8
Muscle Insulin Resistance and the Inflamed Microvasculature: Fire from Within.肌肉胰岛素抵抗与炎症性微血管:来自内部的火灾。
Int J Mol Sci. 2019 Jan 29;20(3):562. doi: 10.3390/ijms20030562.
9
Successful treatment of normokalemic periodic paralysis with hydrochlorothiazide.氢氯噻嗪成功治疗正常血钾型周期性瘫痪。
Brain Dev. 2018 Oct;40(9):833-836. doi: 10.1016/j.braindev.2018.05.011. Epub 2018 Jun 12.
10
Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses.球形脂联素通过AMPK介导的微血管胰岛素反应恢复来改善代谢性胰岛素抵抗。
J Physiol. 2015 Sep 1;593(17):4067-79. doi: 10.1113/JP270371. Epub 2015 Jul 26.